A Novel Aerogel Delivery System Reduces Drug Resistance for Non-Small Cell Lung Cancer Combination Therapy

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Oncology

Background:

• Lung cancer is a leading cause of cancer mortality, with non-small cell lung cancer (NSCLC) being the most common subtype.
• Current targeted therapies for NSCLC face challenges due to drug resistance and systemic toxicity.
• Combination therapy with docetaxel and gefitinib shows potential but is limited by nonspecific drug uptake and side effects.

Purpose of the Study:

• To develop an inhalable aerogel-based nanocarrier for the co-delivery of docetaxel and gefitinib.
• To enhance drug accumulation in lung tumors and minimize systemic toxicity.
• To evaluate the efficacy of this novel delivery system in an NSCLC xenograft model.

Main Methods:

• Development of an aerogel nanocarrier system for co-encapsulating docetaxel and gefitinib.
• Inhalation administration of the nanocarrier in a non-small cell lung cancer xenograft mouse model.
• Assessment of drug distribution, tumor inhibition rate, and mechanisms of action (angiogenesis, apoptosis).

Main Results:

• Inhalation administration led to significant drug enrichment within lung tumors.
• The aerogel nanocarrier achieved a tumor inhibition rate of 55.4% ± 3.6% in the NSCLC model.
• The treatment demonstrated reduced drug resistance compared to monotherapy and suppressed tumor angiogenesis while promoting apoptosis.

Conclusions:

• Inhalable aerogels represent a promising strategy for the effective co-delivery of docetaxel and gefitinib in NSCLC.
• This approach enhances lung tumor targeting and reduces systemic toxicity, offering a potential clinical translation.
• The synergistic effects on angiogenesis and apoptosis contribute to the observed therapeutic efficacy.